Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Change in Acquisitions & Divestments (2016 - 2024)

Sangamo Therapeutics (SGMO) has 15 years of Change in Acquisitions & Divestments data on record, last reported at -$33.6 million in Q3 2024.

  • For Q3 2024, Change in Acquisitions & Divestments fell 170.32% year-over-year to -$33.6 million; the TTM value through Jun 2025 reached -$33.6 million, down 132.58%, while the annual FY2024 figure was $1.1 million, 99.48% down from the prior year.
  • Change in Acquisitions & Divestments reached -$33.6 million in Q3 2024 per SGMO's latest filing, down from $33.6 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $596.0 million in Q4 2021 and bottomed at -$316.2 million in Q3 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $82.6 million, with a median of $78.9 million recorded in 2020.
  • The widest YoY moves for Change in Acquisitions & Divestments: up 444.15% in 2021, down 254.23% in 2021.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $109.5 million in 2020, then skyrocketed by 444.15% to $596.0 million in 2021, then tumbled by 83.29% to $99.6 million in 2022, then tumbled by 79.27% to $20.6 million in 2023, then tumbled by 262.87% to -$33.6 million in 2024.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were -$33.6 million in Q3 2024, $33.6 million in Q2 2024, and $1.1 million in Q1 2024.